Adjuvo: first randomized trial of adjuvant mitotane in adrenocortical carcinoma patients

1 Views

06/15/23

Alfredo Berruti, MD, University of Brescia, Brescia, Italy, provides an overview of the Adjuvo study comparing the efficacy of adjuvant mitotane treatment versus observation on prolonging recurrence-free survival (RFS) in patients with adrenocortical carcinoma at low-intermediate risk of recurrence. Results do not support the routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.